Clinical Trial Quality: “Good Enough” Isn’t Good Enough For Patients
Settling for “good enough” undermines clinical trial quality in drug development and risks trial failure and regulatory rejection. Here’s what pursuing greatness actually requires.
We haven't written up this one. Forbes has the full story — the link below goes straight to it.